Mark L. Perry, Director at Global Blood Therapeutics, Inc. (GBT), sold 106,600 shares at $77.71 ($8.3M) on 2020-05-12, disclosed to the SEC on 2020-05-13.
Open-market sale of $8.3M GBT by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.01 | 2,633 | $195K | 2.3% |
| 2 | $74.01 | 2,633 | $195K | 2.3% |
| 3 | $75.43 | 1,350 | $102K | 1.2% |
| 4 | $75.43 | 1,350 | $102K | 1.2% |
| 5 | $76.28 | 600 | $46K | 0.5% |
| 6 | $77.71 | 13,024 |
| $1.0M |
| 12.2% |
| 7 | $77.71 | 13,024 | $1.0M | 12.2% |
| 8 | $78.65 | 34,698 | $2.7M | 32.8% |
| 9 | $78.65 | 34,698 | $2.7M | 32.8% |
| 10 | $79.17 | 1,295 | $103K | 1.2% |
| 11 | $79.17 | 1,295 | $103K | 1.2% |
| Total | $78.11 avg | 106,600 | $8.3M | 100% |
| Filing → |
| NVDA | SELL | 2023-02-28 | $4.7M | — | Filing → |
| NVDA | SELL | 2022-03-21 | $5.6M | — | Filing → |
| NVDA | SELL | 2021-04-06 | $6.0M | — | Filing → |